XTL Biopharmaceuticals Ltd.
XTLBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, XTL Biopharmaceuticals Ltd. focuses on Biotechnology services and products. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The $5.0M market capitalization puts XTLB squarely in micro-cap range for its industry. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Market Cap
$5.0M
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.36
EPS (Fwd)
—
ROE
-29.3%
ROA
-21.0%
Cash
$76,000
Total Debt
$0
Free CF
-$2.1M
52W Change
-57.9%
Annual Financials
Cash vs Debt
Where XTLB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XTLB finished 23.74% below its 150-day moving average ($2.57) and 28.99% below its 200-day moving average ($2.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XTLB overbought or oversold?
At the October 20, 2026 close, XTLB's RSI(14) was 34.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
XTL Biopharmaceuticals Ltd. reports $76K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$2.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -29.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, XTL Biopharmaceuticals Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XTLB.